Table 1.
Changes in clinical assessments, bone mineral density and laboratory analysis following anti-TNF treatment in AS patients
| Baseline | 6 months | 12 months | P | |
|---|---|---|---|---|
| BASDAI | 5.11 ± 2.1 | 2.78 ± 2.4 | 2.78 ± 2.5 | < 0.001 |
| BASFI | 5.40 ± 2.7 | 2.96 ± 2.6 | 2.85 ± 2.7 | < 0.001 |
| BASMI | 4.06 ± 2.7 | 3.23 ± 2.6 | 3.07 ± 2.7 | 0.003 |
| AsQoL, score | 10.03 ± 5.2 | 6.43 ± 6.4 | 6.40 ± 6.05 | 0.001 |
| ESR, mm/hr | 23.75 ± 23.1 | 8.16 ± 15.6 | 7.3 ± 13.1 | < 0.001 |
| C-reactive protein, mg/dL | 37.03 ± 47.9 | 3.35 ± 4.1 | 7.21 ± 20.1 | < 0.001 |
| MMP-3, ng/mL | 48.6 ± 42.5 | 21.6 ± 22.5 | 23.3 ± 30.8 | < 0.001 |
| BMD lumbar spine, g/cm2 | 1.032 ± 0.175 | 1.049 ± 0.169 | 1.065 ± 0.169 | < 0.001 |
| BMD femoral neck, g/cm2 | 0.864 ± 0.160 | 0.865 ± 0.159 | 0.864 ± 0.161 | 0.051 |
| BMD total femur, g/cm2 | 0.990 ± 0.165 | 0.986 ± 0.165 | 0.999 ± 0.171 | 0.981 |
| Sclerostin, pmol/L | 60.5 ± 32.7 | 67.1 ± 31.9 | 72.7 ± 32.3 | < 0.001 |
| Sclerostin binding to LRP6, OD450 | 0.61 ± 0.13 | ND | 0.60 ± 0.14 | 0.472 |
Values are expressed as mean (SD). AS, ankylosing spondylitis; BASDAI, Bath AS Disease Activity Index; BASFI, Bath AS Functional Index; BASMI, Bath AS Metrology Index; ASQoL, AS quality of life questionnaire; BMD, bone mineral density; ESR, erythrocyte sedimentation rate; MMP-3, matrix metalloproteinase 3; LRP6, low-density lipoprotein receptor-related protein 6; OD, optical density; ND, not done.